Trulieve granted four dispensary permits and Solevo Wellness granted three dispensary permits by the West Virginia Office of Medical Cannabis

Trulieve Cannabis Corp . (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States and the largest cannabis company in Florida announced today that it has been awarded a four dispensary permits by the West Virginia Office of Medical Cannabis. In addition, Trulieve’s Pennsylvania acquisition, Solevo Wellness, was awarded three permits. The dispensary selection adds to the processor permit issued by the state in November 2020 .


As announced January 29, 2021 by the Office of Medical Cannabis, Trulieve received permits for dispensaries in South Charleston in the greater Charleston area, Weston , Buckhannon , and Morgantown near the Pennsylvania border.  Solevo received two permits in Morgantown and one in Parkersburg . These locations are spread across five counties and include a number of the largest populated areas in the state.

“We are excited to have these four dispensary permits awarded and to add to the processor permit already granted by West Virginia ,” said Kim Rivers , CEO of Trulieve. “We are looking forward to expanding into our sixth state this year. Trulieve’s mission has always been to provide the highest level of cannabis products and customer experience through authentic and reciprocal relationships with its customers and patients. The dispensaries will further support that mission by introducing new patient populations to the Trulieve brand and offering relief they can rely on through the Company’s safe, quality products.”

Trulieve is committed to investing in the communities it operates in and will approach West Virginia with the same high level of integrity, focus on diversity, equity, and inclusion, and dedication to a variety of quality products. The West Virginia Medical Cannabis Act permits patients with serious medical conditions to procure medical cannabis in the following forms: pill; oil; topical forms including gels, creams or ointments; forms for vaporization or nebulization, dry leaf or plant form; tincture; liquid; or dermal patch.  Patient registration in the state opens this week.

About Trulieve

Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida , as well as directly to patients via home delivery. Trulieve also operates in California , Massachusetts , Connecticut and Pennsylvania . Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX Best Market under the symbol TCNNF.

This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

To learn more about Trulieve, visit www.Trulieve.com .

The Canadian Securities Exchange has not reviewed, approved or disapproved the ‎content of this news release.‎

Forward-Looking Statements
This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company and statements with regard to the Report and the Company’s response thereto. Words such as “expects”, “continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

SOURCE Trulieve Cannabis Corp.

Cision View original content: http://www.newswire.ca/en/releases/archive/February2021/01/c5666.html

News Provided by Canada Newswire via QuoteMedia

Drug Emporium is a chain of “big box” pharmacies in Texas, Arkansas, and Louisiana with standard pharmacy departments as well as “store-within-a-store” features such as “Vitamins Plus”. This month, the Company’s KOIOS™ and Fit Soda™ beverage products will be placed in select Texas locations of Drug Emporium, complementing existing placements of the Company’s products in the state of Texas, including in more than 100 HEB supermarkets.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning this month, all five flavours of its KOIOS ™ nootropic beverage and all four flavours of its Fit Soda ™ functional beverage will be carried in select Texas locations of Drug Emporium, a “big box” pharmacy chain with stores in Texas (population 29 million), Arkansas (population 3 million), and Louisiana (population 4.65 million). In late 2020, the Company announced that its Fit Soda ™ functional beverage product is now carried in more than 100 HEB supermarkets in Texas . Additionally, the Company announced last week that its KOIOS ™ nootropic beverage product was to be added to all locations of Louisiana supermarket chain Matherne’s including its storefront located across from the Louisiana State University’s Tiger Stadium which is the eighth-largest stadium in the world. The Company has sustained its focus on placing its beverage products with regional grocery chains who can play a key role in accelerating market penetration in a given geographic region. By adding to its existing presence in the southeastern United States through local chains such as Drug Emporium and national banner retailers such as Walmart, the Company believes that it is favourably positioned to gain greater market share in the functional beverages category. The Company’s beverage products are currently sold in more than 4,000 stores in the United States.

Keep reading... Show less

Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF), is pleased to announce that, further to the Company’s announcement on 15 February 2021, the change of name from World High Life Plc to Love Hemp Group PLC has become effective

All share certificates that are presently in the hands of investors will be valid and do not need to be exchanged for new share certificates.

Keep reading... Show less

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less